An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs N acetyl D mannosamine (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- 27 Nov 2024 Planned initiation date changed from 26 Nov 2024 to 2 Dec 2024.
- 21 Nov 2024 Planned initiation date changed to 26 Nov 2024.
- 04 Nov 2024 New trial record